Cancer

December 1, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as GRHL3, BIRC5,   p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 2/December/2018, 12.08 am

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology […]
November 19, 2018

A sweet way to treat Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors PTPN14 and RB1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up-regulation of its target gene, 19/November/2018, 11.58 pm

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more […]
November 19, 2018

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as KISS1, RECK, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 19/November/2018, 11.38 pm

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows […]
November 19, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SOCS6, Gelsolin,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/November/2018, 11.18 pm

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology […]